Key Takeaways REGN Q1 results hinge on Dupixent profits and Eylea HD sales offsetting weaker Eylea demand.Eylea faces pressure from Vabysmo, while Eylea HD demand and label expansions may lift franchise sales.Dupixent sales rose 30.8% per SNY, boosting REGN profit share alongside Libtayo growth.Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. (REGN) reports first-quarter 2026 results on April 29, 2026.The Zacks Consensus Estim ...